Follow The Filings

NMTC NeuroOne Medical Technologies

NeuroOne Medical Technologies earnings company data as of 4:51 AM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 15 Dec EPS — — —
Rev — — —
FY2026 Q3 13 Aug EPS — -0.23 —
Rev — — —

Insider trades

Open-market buys and sales by NMTC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NMTC insider trades
  • $737K bought by 1 insider
  • $55K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. David J. Wambeke Chief Business Officer
    Buy
    $67K 33,333 shares at $2.01 +20% to stake
    Traded Aug 27 Filed Sep 8
  2. Mark Christianson Market Development Director
    Sale
    $32K 10,000 shares at $3.18 33% of stake
    Traded Jun 30 Filed Jul 2
  3. Mark Christianson Business Development Director
    Sale
    $11K 15,363 shares at $0.7400 7.2% of stake
    Traded Mar 30 Filed Apr 1
  4. Mark Christianson Business Development Director
    Sale
    $734 917 shares at $0.8000 0.4% of stake
    Traded Mar 12–13 Filed Mar 16
  5. Mark Christianson Business Development Director
    Sale
    $11K 13,720 shares at $0.8000 6% of stake
    Traded Mar 10–11 Filed Mar 12
  6. David J. Wambeke Chief Business Officer
    Buy
    $670K 1,000,000 shares at $0.6700 New stake
    Traded Mar 1 Filed Mar 3

Also filed in the last 12 months, not counted as buying or selling: 9 share withholdings for taxes and 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 2.02,8.01,9.01
8-K 8.01,9.01
8-K 2.02,9.01
10-Q QUARTERLY REPORT
SCHEDULE 13G/A —
10-Q/A AMENDMENT NO. 1 TO FORM 10-Q
8-K 8.01,9.01
424B5 PROSPECTUS SUPPLEMENT
8-K 4.02,7.01,9.01
8-K 2.02,9.01
10-Q QUARTERLY REPORT
8-K 8.01
8-K 5.02,9.01
SCHEDULE 13G —
8-K 5.03,9.01
8-K 5.02,5.07,9.01
DEF 14A PROXY STATEMENT
8-K 8.01
10-Q QUARTERLY REPORT
8-K 2.02,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.